Zobrazeno 1 - 10
of 186
pro vyhledávání: '"David D.L. Bowtell"'
Publikováno v:
Journal of Clinical Oncology. 41:1770-1773
Autor:
Mohammad Reza Eftekhariyan Ghamsari, Nadia Traficante, Nirashaa Bound, Cordelia D. McGehee, Inger Olesen, Kristy Shield-Artin, Clare L. Scott, Elizabeth Lieschke, Rachel M. Hurley, Anna deFazio, Ashan Musafer, Nicola Waddell, Marc R. Radke, Matthew Wakefield, Alexander Dobrovic, Ksenija Nesic, Genevieve Dall, Maria I. Harrell, Olga Kondrashova, Damien Kee, S. John Weroha, Scott H. Kaufmann, Katia Nones, David D.L. Bowtell, Cassandra J. Vandenberg, Orla McNally, Elizabeth M. Swisher, Gwo-Yaw Ho, Zi Qing Chai
Publikováno v:
Cancer Research. 81:4709-4722
In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defective homologous recombination and are emerging biomarkers of PARP inhibitor (PARPi) sensitivity. RAD51C promoter methylatio
Autor:
Omali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, Sivatharsny Srirangan, Cristina Mapagu, Judy Kirk, Paul R. Harnett, Rosemary L. Balleine, David D.L. Bowtell, Goli Samimi, Alison H. Brand, Deborah J. Marsh, Philip Beale, Lyndal Anderson, Natalie Bouantoun, Pamela Provan, Susan J. Ramus, Anna DeFazio, Michael Friedlander
Publikováno v:
Translational Oncology. 31:101638
Autor:
Anil K. Sood, Shama Virani, Kathleen R. Cho, Nicolas Wentzensen, Britton Trabert, Paul D.P. Pharoah, Stephen J. Chanock, Barbara M. Norquist, Jae Weon Kim, Paul Brennan, Keiichi Fujiwara, Usha Menon, Jean Emmanuel Kurtz, Glauco Baiocchi, David D.L. Bowtell, Shelley T. Tworoger, Douglas A. Levine, Citadel J Cabasag, Martin Köbel, Renée T. Fortner
Publikováno v:
Carcinogenesis. 42:785-793
Recently, ovarian cancer research has evolved considerably because of the emerging recognition that rather than a single disease, ovarian carcinomas comprise several different histotypes that vary by etiologic origin, risk factors, molecular profiles
Autor:
Elizabeth L. Christie, David Shi Hao Liu, David D.L. Bowtell, Chris Mitchell, Walid J Azar, George Au-Yeung
Publikováno v:
Cancer Research. 80:4960-4971
Ovarian clear cell adenocarcinoma (OCCA) is characterized by a particularly poor response to conventional chemotherapy and a short overall survival time in women with established disease. The development of targeted treatments for OCCA relies on a be
Autor:
Sven Mahner, Robertson Mackenzie, Aline Talhouk, Linda E. Kelemen, Gottfried E. Konecny, Jennifer Alsop, Rosalind Glasspool, Chiu-Chen Tseng, Joy Hendley, Dennis J. Slamon, Jennifer A. Doherty, Andrew Berchuck, Anna H. Wu, Anna M. Piskorz, Chen Wang, Cristina Rodríguez-Antona, D.G.H. de Silva, Valerie Rhenius, Peter A. Fasching, Stacey J. Winham, Gary L. Keeney, Teodora Goranova, Joshy George, Jan Lubinski, Michelle J. Henderson, Rex C. Bentley, Jenny Lester, Sabine Behrens, Joellen M. Schildkraut, Michael E. Carney, Timothy Budden, David G. Huntsman, Oleg Oszurek, Michael S. Anglesio, Jacek Gronwald, Ruby Yun-Ju Huang, Martin Köbel, Javier Benitez, Martin Widschwendter, Melissa C. Larson, Raghwa Sharma, Clara Bodelon, Usha Menon, Janusz Menkiszak, Blake Gilks, María Josefa Mosteiro García, Jesús García-Donas, Wafaa Elatre, Scott H. Kaufmann, Paul Haluska, Pamela J. Thompson, Boris Winterhoff, Susan J. Ramus, Louise A. Brinton, Simon A. Gayther, Mary Anne Rossing, Georgia Chenevix-Trench, Hugh Luk, Jolanta Lissowska, Marc T. Goodman, Billy Chen, Beth Y. Karlan, Naveena Singh, Sian Fereday, Mark E. Sherman, Ana Osorio, Lynne R. Wilkens, Maria P. Intermaggio, Brenda Y. Hernandez, Britton Trabert, Esther Herpel, Mercedes Jimenez-Linan, Janine Senz, Geyi Liu, Celeste Leigh Pearce, Samuel C Y Leong, Iain A. McNeish, Isabelle Ray-Coquard, Susana Banerjee, Malcolm C. Pike, Liz-Anne Lewsley, Helen Steed, Honglin Song, Samantha Hinsley, David D.L. Bowtell, James D. Brenton, Holly R. Harris, Tuan Zea Tan, Cezary Cybulski, Alicia Beeghly-Fadiel, A. Toloczko, Nikilyn Nevins, Robert S. Brown, Darren Ennis, Stephanie Chen, Euan A. Stronach, José Palacios, Sandra Orsulic, Anna deFazio, Geoff Macintyre, Kara L. Cushing-Haugen, Mila Volchek, Aleksandra Gentry-Maharaj, Jenny Chang-Claude, Ellen L. Goode, Paul D.P. Pharoah, Hanwei Sudderuddin, Stefan Kommoss, Derek S. Chiu, Huei San Leong, Peter Sinn, Catherine J. Kennedy, Chloe Karpinskyj, Alison Brand, Amy Lum, Veronica Chow, Nicolas Wentzensen, Tayyebeh M. Nazeran, Nadia Traficante, Dustin Johnson, Yoke-Eng Chiew, Casey S. Greene, Jennifer M Koziak, Renée T. Fortner
Publikováno v:
Clinical Cancer Research. 26:5411-5423
Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility h
Autor:
Ken Doig, Andrew J. Colebatch, Devbarna Sinha, Christopher P. Mintoff, Grant A. McArthur, Paul Yeh, Carleen Cullinane, Maria Joao Silva, Shahneen Sandhu, David E. Gyorki, Mark Shackleton, Kathryn Alsop, Gisela Mir Arnau, Anthony T. Papenfuss, Sarah Ftouni, David D.L. Bowtell, Jason Li, Sarah-Jane Dawson, Jeanette Raleigh, Fergal C. Kelleher, Athena Hatzimihalis, Benjamin Brady, Mark A. Dawson, Stephen Q. Wong, Rodney J. Hicks, Heather Thorne, Jason Callahan, Damien Kee, Ismael A. Vergara, Timothy Semple
Publikováno v:
JCO precision oncology. 1
Purpose Circulating tumor DNA (ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in metabolic disease burden assessed by 18F-labeled fluorodeoxyglucose posi
Autor:
Yi An Ko, Graham R. Taylor, Alison Freimund, Marisa Grossi, Arthur Hsu, Clare J. Love, Kathryn Alsop, Gwo-Yaw Ho, Matthew Wakefield, Michael A. Quinn, Orla McNally, Alexander Dobrovic, Paul Waring, Leakhena Leas, Tiffany Boughtwood, David D.L. Bowtell, Olga Kondrashova, Sumitra Ananda, Yada Kanjanapan, Deborah Neesham, Danny Rischin, Michael Christie, Linda Mileshkin, Giada V. Zapparoli, George Au-Yeung, Sebastian Lunke, Nadia Traficante, Clare L. Scott, Anne Hamilton
Publikováno v:
JCO precision oncology. 3
PURPOSE The ALLOCATE study was designed as a pilot to demonstrate the feasibility and clinical utility of real-time targeted molecular profiling of patients with recurrent or advanced ovarian cancer for identification of potential targeted therapies.
Autor:
Yenarae Lee, Andrew D. Cherniack, Ursula A. Matulonis, Kristopher A. Sarosiek, Elizabeth L. Christie, Levi A. Garraway, Maria B. Baco, Ioannis K. Zervantonakis, Weiqun Zhang, Jeremy Ryan, Guo Wei, Federica Piccioni, Joan Montero, Felice J. Liang, Sasha Pantel, Elizabeth H. Stover, Matthew Meyerson, Maya K. Gelbard, Ofir Cohen, Cory M. Johannessen, David D.L. Bowtell, Amy Goodale, Adam G. Presser, Jennifer L. Guerriero, Matthew G. Rees, Mukta Bagul, Anthony Letai, Yvonne Y. Li, Patrick Bhola
Publikováno v:
Mol Cancer Res
High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy, but most patients relapse with chemotherapy-resistant disease. To systematically identify genes modulating chemotherap
Autor:
Georgia Chenevix-Trench, Jan Pyman, David G. Hunstman, Hugo Saunders, Linda Mileshkin, Dane Cheasley, Alison Maree Hadley, Nadia Traficante, Clare L. Scott, Diane Provencher, Niko Thio, Clare G Fedele, Joy Hendley, Jason Li, Michael S. Anglesio, Prue E. Allan, Siobhan Hughes, Magnus Zethoven, Timothy Semple, Tom Jobling, Martin Köbel, Michael Christie, Goli Samimi, Kylie L. Gorringe, Anne Marie Mes-Masson, George Au-Yeung, Yoland Antill, Andrew N. Stephens, Cécile Le Page, Carolina Salazar, Kathryn Alsop, Anna deFazio, Kurosh Rahimi, Richard Lupat, Orla McNally, Georgina L Ryland, Jessica N. McAlpine, Ian G. Campbell, Renee Demeo, Rhiannon Dudley, Simone M Rowley, Michael Churchman, C. Blake Gilks, Gwo-Yaw Ho, Stephen B. Fox, Yoke Eng Chiew, Sally M Hunter, David D.L. Bowtell, Charlie Gourley, Catherine J. Kennedy, Zhongyue Xing, Scott H. Kaufmann, Nicole Fairweather, Kimberly R. Kalli, Alison Brand, Ragwha Sharma, Maret Böhm, Sian Fereday, Matthew Wakefield, Michelle C. Torres, Alice J. Sharpe, Neville F. Hacker, Sumitra Ananda, Kaushalya C. Amarasinghe
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
Cheasley, D, J Wakefield, M, E Allan, P, L Ryland, G, Alsop, K, C Amarasinghe, K, Ananda, S, S Anglesio, M, Au-Yeung, G, Bohm, M, DL Bowtell, D, Brand, A, Chenevix-Trench, G, Christie, M, Chew, Y-E, Churchman, M, DeFazio, A, Demeo, R, Dudley, R, Fairweather, N, G Fedele, C, Fereday, S, B Fox, S, Gilks, C B, Gourley, C, F Hacker, N, M Hadley, A, Hendley, J, Ho, G-Y, Hughes, S, G Hunstman, D, M Hunter, S, W Jobling, T, R Kalli, K, H Kaufmann, S, J Kennedy, C, Kobel, M, Le Page, C, Li, J, Lupat, R, M McNally, O, N McAlpine, J, Mes-Masson, A-M, Mileshkin, L, M Provencher, D, Pyman, J, Rahimi, K, M Rowley, S, Salazar, C, Samimi, G, Saunders, H, Semple, T, Sharma, R, J Sharpe, A, N Stephens, A, Thio, N, C Torres, M, Traficante, N, Xing, Z, Zethoven, M, C Antill, Y, L Scott, C, G Campbell, I & Gorringe, K 2019, ' The Molecular Origin and Taxonomy of Mucinous Ovarian Carcinoma ', Nature Communications . https://doi.org/10.1038/s41467-019-11862-x
Nature Communications
Cheasley, D, J Wakefield, M, E Allan, P, L Ryland, G, Alsop, K, C Amarasinghe, K, Ananda, S, S Anglesio, M, Au-Yeung, G, Bohm, M, DL Bowtell, D, Brand, A, Chenevix-Trench, G, Christie, M, Chew, Y-E, Churchman, M, DeFazio, A, Demeo, R, Dudley, R, Fairweather, N, G Fedele, C, Fereday, S, B Fox, S, Gilks, C B, Gourley, C, F Hacker, N, M Hadley, A, Hendley, J, Ho, G-Y, Hughes, S, G Hunstman, D, M Hunter, S, W Jobling, T, R Kalli, K, H Kaufmann, S, J Kennedy, C, Kobel, M, Le Page, C, Li, J, Lupat, R, M McNally, O, N McAlpine, J, Mes-Masson, A-M, Mileshkin, L, M Provencher, D, Pyman, J, Rahimi, K, M Rowley, S, Salazar, C, Samimi, G, Saunders, H, Semple, T, Sharma, R, J Sharpe, A, N Stephens, A, Thio, N, C Torres, M, Traficante, N, Xing, Z, Zethoven, M, C Antill, Y, L Scott, C, G Campbell, I & Gorringe, K 2019, ' The Molecular Origin and Taxonomy of Mucinous Ovarian Carcinoma ', Nature Communications . https://doi.org/10.1038/s41467-019-11862-x
Nature Communications
Mucinous ovarian carcinoma (MOC) is a unique subtype of ovarian cancer with an uncertain etiology, including whether it genuinely arises at the ovary or is metastatic disease from other organs. In addition, the molecular drivers of invasive progressi